Winners received prestigious award in recognition of latest innovations in advancement in life sciences ...

Zenvia Inc. (the "Company"), the leading cloud-based CX platform in Latin America, empowering companies to transform their customer journeys, today announced that its fiscal 2024 third quarter and ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.

Modular Devices is excited to announce the addition of David Frank as Fractional Chief Commercial Officer, reinforcing the company's commitment to strategic growth and leadership within the cleanroom ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

AstraZeneca Plc started the week with a market valuation of about £171 billion ($222 billion). By the close on Thursday it ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. Antibody drug conjugates ...

The ROS-1 NSCLC current market is mainly dominated by tyrosine kinase inhibitors such as XALKORI at present and is anticipated to be dominated ...

Hepatocellular carcinoma (HCC) is the most common type of liver cancer and ranks among the leading causes of cancer-related deaths globally. Traditional treatment methods, including surgical resection ...

datopotamab deruxtecan is one of the three lead ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced ...

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...